Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
RNA interference (RNAi) is a universal and evolutionarily conserved phenomenon of post-transcriptional gene silencing by means of sequence-specific mRNA degradation, triggered by small double-stranded RNAs. Because this mechanism can be efficiently induced in vivo by expressing target-complementary short hairpin RNA (shRNA) from non-viral and viral vectors, RNAi is attractive for functional genomics and human therapeutics. Here we systematically investigate the long-term effects of sustained high-level shRNA expression in livers of adult mice. Robust shRNA expression in all the hepatocytes after intravenous infusion was achieved with an optimized shRNA delivery vector based on duplex-DNA-containing adeno-associated virus type 8 (AAV8). An evaluation of 49 distinct AAV/shRNA vectors, unique in length and sequence and directed against six targets, showed that 36 resulted in dose-dependent liver injury, with 23 ultimately causing death. Morbidity was associated with the downregulation of liver-derived microRNAs (miRNAs), indicating possible competition of the latter with shRNAs for limiting cellular factors required for the processing of various small RNAs. In vitro and in vivo shRNA transfection studies implied that one such factor, shared by the shRNA/miRNA pathways and readily saturated, is the nuclear karyopherin exportin-5. Our findings have fundamental consequences for future RNAi-based strategies in animals and humans, because controlling intracellular shRNA expression le…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular toxicity can, for example, be observed in rAAV shRNA overexpression studies in which ubiquitous promoters were used that caused saturation of cellular miRNA pathways [88].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“However, the relatively large size, the requirement that the transcript starts with a G or A, the sometimes too active transcription, and the sensitivity to specific cellular profiles make the human U6 promoter a less versatile promoter [88,131,132].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [88]
In the citing paper
“Consistent with this possibility, when multiple miRNAs are packaged within a single construct, they may compete for processing by the cellular miRNA biogenesis machinery, leading to reduced efficiency in individual miRNA maturation and function 44,45 .”
From rAAV-mediated Multi-miRNA Delivery Targeting MAPK Pathway Suppresses Laser-induced Choroidal Neovascularization in Mice (2026) · cites this paper as [44]
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Hannon, G. J. (2002) · Nature · doi:10.1038/418244a · Cited by 3,538
Identification of tissue-specific microRNAs from mouse
Lagos-Quintana, M., Rauhut, R., Yalcin, A., Meyer, J., Lendeckel, W., & Tuschl, T. (2002) · Current Biology · doi:10.1016/s0960-9822(02)00809-6 · Cited by 3,355
Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs
Yi, R., Qin, Y., Macara, I. G., & Cullen, B. R. (2003) · Genes & Development · doi:10.1101/gad.1158803 · Cited by 3,010
Nuclear Export of MicroRNA Precursors
Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004) · Science · doi:10.1126/science.1090599 · Cited by 2,714
Mechanisms of gene silencing by double-stranded RNA
Meister, G., & Tuschl, T. (2004) · Nature · doi:10.1038/nature02873 · Cited by 2,539
Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA
Jopling, C. L., Yi, M., Lancaster, A. M., Lemon, S. M., & Sarnow, P. (2005) · Science · doi:10.1126/science.1113329 · Cited by 2,521
Self-citationExportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs
BOHNSACK, M. T., CZAPLINSKI, K., & GÖRLICH, D. (2004) · RNA · doi:10.1261/rna.5167604 · Cited by 1,433
Cited by
Items 701–800 of 1,001
Purow, B. W. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0449-5 · Cited by 35
“[59].”
Watanabe, C. K., Cuellar, T. L., & Haley, B. (2016) · RNA Biology · doi:10.1080/15476286.2015.1128062 · Cited by 33
“RNAs, could be a contributing factor to the previously observed shRNA-dependent toxicity.(9,12)”
BackgroundEffective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold
Xie, J., Tai, P. W. L., Brown, A., Gong, S., Zhu, S., Wang, Y., Li, C., Colpan, C., Su, Q., He, R., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.018 · Cited by 35
“However, high levels of AAV-delivered shRNAs can perturb the RNAi machinery, leading to cellular toxicity.(4,5) Reducing the amount of shRNA by lowering vector doses, selecting less efficient AAV serotypes, or using weaker RNA polymerase (Pol) II promoters, instead of a strong and constitutive H1 or U6 Pol III promote…”
BackgroundReichenbach, P., Attianese, G. M. P. G., Ouchen, K., Cribioli, E., Triboulet, M. M., Ash, S., Saillard, M., de Silly, R. V., Coukos, G., & Irving, M. B. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01013-5 · Cited by 33
Apolipoprotein B Knockdown by AAV-delivered shRNA Lowers Plasma Cholesterol in Mice
Koornneef, A., Maczuga, P., van Logtenstein, R., Borel, F., Blits, B., Ritsema, T., van Deventer, S. J. H., Petry, H., & Konstantinova, P. S. (2011) · Molecular Therapy · doi:10.1038/mt.2011.6 · Cited by 36
“AAV-shA10 administration does not cause severe toxicity in mice It has been reported that high levels of shRNA expression can lead to severe liver toxicity symptoms like weight loss, activation of liver-specific transaminases, changes in liver morphology, or oversaturation of the cellular miRNA machinery [21].”
BackgroundInfluentialPiras, B. A., O’Connor, D. M., & French, B. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075894 · Cited by 33
Development of gene therapy for treatment of age‐related macular degeneration
Askou, A. L. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12452 · Cited by 35
“However, for gene therapy applications, there are serious disadvantages of using strong polymerase III promoters including cellular toxicity due to oversaturation of the endogenous RNAi pathway (Grimm et al. 2006).”
BackgroundInfluentialLentiviral Vector-Mediated RNA Silencing in the Central Nervous System
Hutson, T. H., Foster, E., Moon, L. D. F., & Yáñez‐Muñoz, R. J. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2013.016 · Cited by 35
“…in gene expression, which may contribute to the cytotoxicity observed in vitro and lethality in vivo after high-level shRNA expression in the CNS or liver (Grimm et al. , 2006, 2010; McBride et al. , 2008; Boudreau et al. , 2009; Ehlert et al ., 2010; Khodr et al ., 2011; Martin et al ., 2011).”
Kotowska‐Zimmer, A., Ostrovska, Y., & Olejniczak, M. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.12.012 · Cited by 34
Non-Coding RNAs as Therapeutic Targets in Hepatocellular Cancer
Braconi, C., & Patel, T. C. (2012) · Current Cancer Drug Targets · doi:10.2174/15680096112091073 · Cited by 32
Structural and biochemical advances in mammalian RNAi
Collins, R. E., & Cheng, X. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21069 · Cited by 36
“Overload of the miRNA pathway by a number of different viral-delivered short hairpin vectors caused fatality in mice in a dose-dependent manner [Grimm et al., 2006].”
BackgroundIncreasing the Robustness and Validity of RNAi Screens
Haney, S. A. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.8.1037 · Cited by 35
“Problems with high expression have been noted in vivo [37].”
BackgroundMicroRNAs: novel biomarkers for lung cancer diagnosis, prediction and treatment
Wang, Q., Wang, S., Wang, H., Li, P., & Ma, Z. (2012) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.011192 · Cited by 31
Challagulla, A., Jenkins, K. A., O’Neil, T. E., Shi, S., Morris, K. R., Wise, T. G., Paradkar, P. N., Tizard, M. L., Doran, T. J., & Schat, K. A. (2021) · Microorganisms · doi:10.3390/microorganisms9010164 · Cited by 31
“Previously, studies on the stable expression of small RNA molecules (such as shRNAs) in mice [15] and pigs [16] showed toxicity issues due to oversaturation of the cellular miRNA pathway.”
BackgroundEngineering the Mouse Genome to Model Human Disease for Drug Discovery
Köentgen, F., Süss, G., & Näf, D. (2009) · Methods in molecular biology · doi:10.1007/978-1-60761-058-8_4 · Cited by 32
Inhibition of Dengue Virus 2 Replication by Artificial MicroRNAs Targeting the Conserved Regions
Pei-wen, X., Xie, Y., Zhang, X., Huang, H., He, L.-N., Wang, X., & Wang, S. (2013) · Nucleic Acid Therapeutics · doi:10.1089/nat.2012.0405 · Cited by 34
“…siRNA without appropriate chemical modification will be sensitive to interferon systems, and short hairpin RNAs (shRNAs) expressed from Pol-3 promoters (especially U6) were possible to saturate the Dicer or other complexes in RNA silencing, which could cause serious effects (Grimm et al., 2006).”
BackgroundMethodInfluentialThe TRAF-Interacting Protein (TRIP) Is a Regulator of Keratinocyte Proliferation
Almeida, S. M., Ryser, S., Obarzanek-Fojt, M., Hohl, D., & Huber, M. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.329 · Cited by 35
“Massive overexpression of shRNAs can lead to cell cytotoxicity (Bridge et al., 2003; Sledz et al., 2003; Cullen, 2006; Grimm et al., 2006).”
BackgroundHentzschel, F., Hammerschmidt-Kamper, C., Börner, K., Heiß, K., Knapp, B. L., Sattler, J. M., Kaderali, L., Castoldi, M., Bindman, J. G., Malato, Y., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.172 · Cited by 32
Self-citationNovel HIV-1 therapeutics through targeting altered host cell pathways
Coley, W., Kehn‐Hall, K., Duyne, R. V., & Kashanchi, F. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903257781 · Cited by 32
“The delivery of siRNAs or siRNA precursor hairpins (shRNA) can have several adverse side effects such as the induction of the type-I IFN response [136,137], saturation of the microRNA enzymes [138], and off-target effects [139,140].”
Kienle, E., Senís, E., Börner, K., Niopek, D., Wiedtke, E., Große, S., & Grimm, D. (2012) · Journal of Visualized Experiments · doi:10.3791/3819 · Cited by 31
Self-citationMicroRNA and Brain Tumors: A Cause and a Cure?
Mathupala, S. P., Mittal, S., Guthikonda, M., & Sloan, A. E. (2007) · DNA and Cell Biology · doi:10.1089/dna.2006.0560 · Cited by 31
“…to saturate trans-nuclear export machinery (i.e., in this case, Exportin-5–mediated miRNA translocation), leading to competition with the normal export of endogenous pre-miRNAs, resulting in adverse effects in the targeted tissue as well as on the organism (Grimm et al. , 2006; Marsden, 2006).”
Towards a durable RNAi gene therapy for HIV-AIDS
Berkhout, B., & ter Brake, O. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712590802653619 · Cited by 31
“First, it was recently shown that in vivo expression of shRNAs led to fatality in mice due to saturation of the mi/siRNA pathways [97] .”
BackgroundZhou, X., Xu, F., Mao, H., Ji, J., Yin, M., Feng, X., & Guang, S. (2014) · Genetics · doi:10.1534/genetics.113.159780 · Cited by 31
“In addition, high concentrations of siRNA can induce an interferon response or global changes in gene expression by competing with limiting factors involved in the biogenesis and function of the endogenous RNAi pathway (Grimm et al. 2006).”
BackgroundMaepa, M. B., Ely, A., Grayson, W., & Arbuthnot, P. B. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.007 · Cited by 32
“Demonstration that expression of HBV-targeting shRNAs from a U6 promoter may cause lethal toxicity in vivo was an important development.(12,18) The limited range of transcriptional control by Pol III promoters is a drawback for their therapeutic application.”
BackgroundInfluentialRNAi-Based Strategies for Cyclooxygenase-2 Inhibition in Cancer
Strillacci, A., Griffoni, C., Valerii, M. C., Lazzarini, G., Tomasi, V., & Spisni, E. (2010) · BioMed Research International · doi:10.1155/2010/828045 · Cited by 32
“This may be due to the saturation of the cellular machinery deputed to endogenous miRNAs processing and exportation [88] causing the induction of nonsequencespecific silencing pathway (e.”
Mukherjee, S., Mahata, B., Mahato, B., & Adhya, S. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn017 · Cited by 31
“Moreover, short hairpin RNAs, which generate siRNAs intracellularly, have been reported to have in vivo toxicity ( 23 ).”
BackgroundPotera, C. (2007) · Nature Biotechnology · doi:10.1038/nbt0507-497 · Cited by 31
Ayuk, M. A., Suttiprapa, S., Rinaldi, G., Mann, V. H., Lee, C. M., & Brindley, P. J. (2011) · International Journal for Parasitology · doi:10.1016/j.ijpara.2011.02.004 · Cited by 30
“This may reflect saturation of the cellular microRNA/shRNA pathway leading to competition for limited cellular factors such as nuclear karyopherin exportin-5 (see Grimm et al., 2006; Snøve and Rossi, 2006).”
BackgroundEfficient mammalian germline transgenesis by cis-enhanced Sleeping Beauty transposition
Carlson, D. F., Geurts, A. M., Garbe, J., Park, C. W., Rangel-Filho, A., O’Grady, S. M., Jacob, H. J., Steer, C. J., Largaespada, D. A., & Fahrenkrug, S. C. (2010) · Transgenic Research · doi:10.1007/s11248-010-9386-5 · Cited by 33
“Additionally, the machinery responsible for processing small RNAs is prone to saturation by excess synthetic shRNA (Grimm et al. 2006).”
BackgroundMak, H. K., Yung, J. S. Y., Weinreb, R. N., Ng, S. H., Cao, X., Ho, T. Y. C., Ng, T. K., Chu, W. K., Yung, W., Choy, K. W., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.05.031 · Cited by 31
RNA interference-based therapeutics for shrimp viral diseases
Krishnan, P., Gireesh-Babu, P., Rajendran, K., & Chaudhari, A. (2009) · Diseases of Aquatic Organisms · doi:10.3354/dao02126 · Cited by 33
“They are known to trigger abnormalities in hepatocytes (Grimm et al. 2006) and neurons (Alvarez et al. 2006), probably through saturation of specific steps of this pathway.”
Inhibition of HIV-1 replication with designed miRNAs expressed from RNA polymerase II promoters
Lo, H. M., Chang, T., Yam, P. Y., Marcovecchio, P., Li, S., Zaia, J. A., & Yee, J.-K. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303011 · Cited by 30
Therapy for Dominant Inherited Diseases by Allele-Specific RNA Interference: Successes and Pitfalls
Trochet, D., Prudhon, B., Vassilopoulos, S., & Bitoun, M. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150812115730 · Cited by 30
“This approach may offer an attractive alternative for in vivo tissue-specific expression compared to siRNA or shRNA and to avoid potential toxicity of shRNA expression in vivo [55, 56].”
Maepa, M. B., Crowther, C. E., Ely, A., & Arbuthnot, P. B. (2014) · BioMed Research International · doi:10.1155/2014/718743 · Cited by 30
“Previously it has been reported that expression of anti-HBV shRNAs from a U6 Pol III promoter within adeno-associated vectors resulted in hepatotoxicity [9].”
BackgroundPfister, E. L., Chase, K. O., Sun, H., Kennington, L. A., Conroy, F., Johnson, E., Miller, R., Borel, F., Aronin, N., & Mueller, C. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.011 · Cited by 33
Delivery of Therapeutic RNAi by Nanovehicles
Baigude, H., & Rana, T. M. (2009) · ChemBioChem · doi:10.1002/cbic.200900252 · Cited by 30
Gish, R. G., Satishchandran, C., Young, M. D., & Pachuk, C. J. (2011) · Antiviral Therapy · doi:10.3851/imp1798 · Cited by 30
“In this study evaluating RNAi-based anti-HBV in mice, shRNA-related microRNA oversaturation resulted in high rodent fatality rates [6].”
BackgroundCountering hepatitis B virus infection using RNAi: how far are we from the clinic?
Ivacik, D., Ely, A., & Arbuthnot, P. B. (2011) · Reviews in Medical Virology · doi:10.1002/rmv.705 · Cited by 29
AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
van der Laan, L. J. W., Wang, Y., Tilanus, H. W., Janssen, H. L. A., & Pan, Q. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.548799 · Cited by 32
“Notably, AAV-mediated expression of shRNA was shown to evoke liver toxicity in mice [83].”
BackgroundLisowiec‐Wąchnicka, J., Bartyś, N., & Pasternak, A. (2019) · Scientific Reports · doi:10.1038/s41598-018-36620-9 · Cited by 31
Schnurri-3 inhibition suppresses bone and joint damage in models of rheumatoid arthritis
Stavre, Z., Kim, J., Yang, Y.-S., Nündel, K., Chaugule, S. R., Sato, T., Park, K. H., Gao, G., Gravallese, E. M., & Shim, J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218019120 · Cited by 31
“Since high levels of AAV-delivered shRNAs can induce cytotoxicity by perturbing the RNAi machinery or exhibit significant off-target silencing (41, 42), in this study the guide strand of a small silencing RNA of shn3 was embedded into the mouse miR-33-derived miRNA scaffold ( amiR-Shn3 ) to limit…”
MethodOECD (2020) · Series on pesticides and on biocides · doi:10.1787/576d9ebb-en · Cited by 70
Maczuga, P., Lubelski, J., van Logtenstein, R., Borel, F., Blits, B., Fakkert, E., Costessi, A., Butler, D., van Deventer, S. J. H., Petry, H., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.160 · Cited by 31
“expressed shRNAs irrespective of hairpin length, sequence and target [17].”
BackgroundCarnero, E., Sutherland, J. D., & Fortes, P. (2011) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.05.004 · Cited by 33
“In fact, overexpression of shRNAs from adenoassociated viral vectors leads to lethality in mice by saturation of the cellular RNAi machinery [96] .”
Pan, Q., de Ruiter, P. E., von Eije, K. J., Smits, R., Kwekkeboom, J., Tilanus, H. W., Berkhout, B., Janssen, H. L. A., & van der Laan, L. J. W. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.02.035 · Cited by 35
“Previous study has reported that adeno-associated virus delivered shRNA in certain context could over-saturate the cellular microRNA pathways [20].”
BackgroundRNAi Therapy for HIV Infection: Principles and Practicalities
Bennasser, Y., Yeung, M. L., & Jeang, K. (2007) · BioDrugs · doi:10.2165/00063030-200721010-00003 · Cited by 31
Novel siRNA delivery strategy: a new "strand" in CNS translational medicine?
Gherardini, L., Bardi, G., Gennaro, M., & Pizzorusso, T. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1310-8 · Cited by 28
“In addition to possible unexpected inflammatory immune reactions and insertional mutagenesis induced within the host genome, siRNA expressed in an uncontrolled manner by viral vectors may provoke cellular toxicity due to oversaturation of RNAi pathways [24].”
A dynamic perspective of RNAi library development
Pan, Q., van der Laan, L. J. W., Janssen, H. L. A., & Peppelenbosch, M. P. (2012) · Trends in biotechnology · doi:10.1016/j.tibtech.2012.01.002 · Cited by 32
MicroRNAs may solve the mystery of chronic hepatitis B virus infection
Wei, Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i30.4867 · Cited by 28
Oligonucleotide-Based Therapies for Renal Diseases
Cartón‐García, F., Saande, C. J., Meraviglia-Crivelli, D., Aldabe, R., & Pastor, F. (2021) · Biomedicines · doi:10.3390/biomedicines9030303 · Cited by 29
Hepatitis B Virus Research in South Africa
Maepa, M. B., Ely, A., Kramvis, A., Bloom, K. M., Naidoo, K., Simani, O. E., Maponga, T. G., & Arbuthnot, P. B. (2022) · Viruses · doi:10.3390/v14091939 · Cited by 29
“Saturation of the endogenous pathway from shRNA expression causes significant toxicity and death in mice [147].”
BackgroundBehind the Scenes of a Small RNA Gene-Silencing Pathway
Ku, G., & McManus, M. T. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.1226 · Cited by 33
Small RNA-Mediated Epigenetic Myostatin Silencing
Roberts, T. C., Andaloussi, S. E., Morris, K. V., McClorey, G., & Wood, M. J. A. (2012) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2012.15 · Cited by 32
Emerging Roles for miRNAs in the Development, Diagnosis, and Treatment of Diabetic Nephropathy
DiStefano, J. K., Taila, M., & Alvarez, M. L. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0386-8 · Cited by 29
Feng, J., Wang, T., Li, Q., Wu, X., & Qin, X. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.08.014 · Cited by 28
RNA-Targeted Therapies and Amyotrophic Lateral Sclerosis
Mathis, S., & Masson, G. L. (2018) · Biomedicines · doi:10.3390/biomedicines6010009 · Cited by 33
Therapeutic Rna Manipulation in Liver Disease
Kerr, T. A., & Davidson, N. O. (2009) · Hepatology · doi:10.1002/hep.23344 · Cited by 31
Jung, H., Kim, S. A., Yang, Y. G., Yoo, H., Lim, S., & Mok, H. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0451-0 · Cited by 28
A novel method for tissue-specific RNAi rescue in Drosophila
Schulz, J. G., David, G., & Hassan, B. A. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp450 · Cited by 31
“Apart from that, activation of the innate immune system (11) and competition with the endogenous RNAi machinery (12) have been reported in mammals.”
Liu, Q., Zhou, H., Zhu, R., Xu, Y., & Cao, Z. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbs073 · Cited by 28
“…[103] Not all pro-inflammatory sequences have been identified Chemical modification [104^106] Not all chemical modifications are compatible with siRNA activity Saturation of the RNAi machinery [115^117] Asymmetric siRNAs with shortened sense strand [107,108] Potential reduction of siRNAs stability.”
BackgroundChen, S. K., Hawley, Z. C. E., Zavodszky, M. I., Hana, S., Ferretti, D., Grubor, B., Hawes, M. C., Xu, S., Hamann, S., Marsh, G., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102057 · Cited by 28
“15,17,18 Neither vector showed evidence of saturating the miRNA machinery in our study, as there was no detectable change in endogenous miRNA expression and no signi fi cant off-target transcriptional changes in the iPSC-derived NGN2 neurons upon transduction of AAV9-miR30a-SOD1 or AAV9-miR155-SOD1.”
BackgroundRNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects
Sneller, L., Lin, C. Y., Price, A. S., Kottilil, S., & Chua, J. V. (2024) · Microorganisms · doi:10.3390/microorganisms12030599 · Cited by 30
Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge
Colombo, S., Zeng, X., Ragelle, H., & Foged, C. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.927439 · Cited by 31
“Finally, very little is known about the potential side effects of Dicer and RISC saturation in primary cells and in vivo [131], although the saturation of RISC has been demonstrated in cultured cells [132].”
BackgroundMichler, T., Große, S., Mockenhaupt, S., Röder, N., Stückler, F., Knapp, B. L., Ko, C., Heikenwälder, M. F., Protzer, U., & Grimm, D. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506172 · Cited by 30
“The same side effects—reduced body weight and ALT elevation—were also observed with an unrelated control shRNA (Fig 5C and D, black), reaffirming reports (Grimm et al, 2006; Beer et al, 2010) that even low levels of shRNA are not fully devoid of detectable side effects.”
BackgroundMethodResultInfluentialSelf-citationLiterature review of baseline information to support the risk assessment of RNAi‐based GM plants
Pačes, J., Nič, M., Novotny, T., & Svoboda, P. (2017) · EFSA Supporting Publications · doi:10.2903/sp.efsa.2017.en-1246 · Cited by 30
“Indeed, lethal nonspecific effects observed with type I shRNAs delivered to the mouse liver by a viral vector were linked to the saturation of Exportin 5 (Grimm et al., 2006) .”
BackgroundTherapeutic applications of group I intron‐based trans‐splicing ribozymes
Lee, C. H., Han, S. R., & Lee, S. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1466 · Cited by 33
Transduction with Lentiviral Vectors Altered the Expression Profile of Host MicroRNAs
Huang, H., Zhang, C., Wang, B., Wang, F., Pei, B., Cheng, C., Yang, W. Z., & Zhao, Z. (2018) · Journal of Virology · doi:10.1128/jvi.00503-18 · Cited by 28
“ery by shRNAs, as reported previously (15, 16).”
BackgroundMethodInfluentialRauschhuber, C., Xu, H., Salazar, F. H., Marion, P. L., & Ehrhardt, A. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1207 · Cited by 29
“HBVU6no.2 was demonstrated to be highly efficient for RNA interferencemediated knockdown of HBV transcription products using a nonviral approach [11] and AAV vectors [12].”
BackgroundMethodSelf-citationAntiviral Stratagems against HIV-1 Using RNA Interference (RNAi) Technology
Vlachakis, D. P., Tsiliki, G., Pavlopoulou, A., Roubelakis, M. G., Tsaniras, S. C., & Κοσσίδα, Σ. (2013) · Evolutionary Bioinformatics · doi:10.4137/ebo.s11412 · Cited by 27
Berger, S. M., Pesold, B., Reber, S., Schönig, K., Berger, A. J., Weidenfeld, I., Miao, J., Berger, M. R., Gruß, O. J., & Bartsch, D. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq616 · Cited by 31
“In fact, strong overexpression of shRNAs in the liver led to severe toxicity and high mortality rate in mice only after a period of 4 weeks (46).”
BackgroundUnexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo
Denovan‐Wright, E. M., Rodríguez-Lebrón, E., Lewin, A. S., & Mandel, R. J. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.11.003 · Cited by 27
Shah, P. S., Pham, N. P., & Schaffer, D. V. (2012) · Molecular Therapy · doi:10.1038/mt.2012.3 · Cited by 27
Microbial linguistics: perspectives and applications of microbial cell-to-cell communication
Mitchell, R. J., Lee, S.-K., Kim, T., & Ghim, C.-M. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.1.1 · Cited by 32
RNA interference and its therapeutic potential against HIV infection
Singh, S. K. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.449 · Cited by 28
“This could have serious toxic and lethal effects on cells [67,97] .”
BackgroundGarber, K. (2017) · Nature Biotechnology · doi:10.1038/nbt.3810 · Cited by 31
Tiash, S., Kamaruzman, N. I., & Chowdhury, E. H. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1396385 · Cited by 26
Bhatnagar, D., Ladhe, S., & Kumar, D. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03446-0 · Cited by 26
Rossi, M., Steklov, M. Y., Huberty, F., Nguyen, T., Marijsse, J., Jacques-Hespel, C., Najm, P., Lonez, C., & Breman, E. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102038 · Cited by 27
“46,76,77 Hence, gene KD using miRNA-based constructs stirred great expectations as a non-gene-edited cell engineering approach, leading to several clinical trials with CAR T cells incorporating miRNA-based KD approaches.”
Myburgh, R., Cherpin, O., Schlaepfer, E., Rehrauer, H., Speck, R. F., Krause, K., & Salmon, P. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.58 · Cited by 26
Development of MicroRNA Therapeutics for Hepatocellular Carcinoma
Aravalli, R. N. (2013) · Diagnostics · doi:10.3390/diagnostics3010170 · Cited by 31
“However, these exogenous miRNAs compete with endogenous ones for miRISC, causing the saturation of miRISC complexes, resulting in the loss of endogenous miRNA regulation and fatality, due to liver toxicity, as demonstrated in animal studies [116,117].”
BackgroundStructural Diversity Repertoire of Gene Silencing Small Interfering RNAs
Chang, C. I., Andrade, H., Dua, P., Kim, S., Li, C. J., & Lee, D.-K. (2011) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0286 · Cited by 27
“, 2009) or even cell death (Grimm et al., 2006), the ability of asymmetric shorter duplex siRNAs to alleviate RNAi machinery saturation indicates that they have a great advantage over classical siRNAs with regard to the development of improved functional genomics tools and therapeutic modalities.”
BackgroundRNA‐Interferenz: von den Grundlagen zur therapeutischen Anwendung
Kurreck, J. (2009) · Angewandte Chemie · doi:10.1002/ange.200802092 · Cited by 30
Preclinical Evaluation of An Anti-HCV miRNA Cluster for Treatment of HCV Infection
Yang, X. J., Marcucci, K. T., Anguela, X. M., & Couto, L. B. (2013) · Molecular Therapy · doi:10.1038/mt.2012.247 · Cited by 28
Stable Argonaute2 overexpression differentially regulates microRNA production
Zhang, X., Graves, P. R., & Zeng, Y. (2008) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2008.11.004 · Cited by 28
Weber, A., Borghouts, C., Brendel, C., Moriggl, R., Delis, N., Brill, B., Vafaizadeh, V., & Groner, B. (2013) · Pharmaceuticals · doi:10.3390/ph6080960 · Cited by 28
“Cytotoxic effects, caused by an excessive shRNA expression and an oversaturation and exhaustion of the shRNA processing machinery [38] can most likely be excluded.”
Li, Z., Zou, Z., Jiang, Z., Huang, X., & Liu, Q. (2019) · Viruses · doi:10.3390/v11060510 · Cited by 28
“Furthermore, specific degradation of complementary mRNA can be triggered by small interfering RNAs (siRNAs) or folded short hairpin RNAs (shRNAs) [98] , which can be explored as an RNA interference strategy, a relatively novel technology that has already been applied to treat many important pathogens, including HIV-1,…”
BackgroundTherapeutic gene silencing strategies for polyglutamine disorders
Scholefield, J., & Wood, M. J. A. (2009) · Trends in Genetics · doi:10.1016/j.tig.2009.11.005 · Cited by 33
Model systems of genetically modified platelets
Thijs, T., Deckmyn, H., & Broos, K. (2011) · Blood · doi:10.1182/blood-2011-10-381715 · Cited by 28
Brown, L. J., Longacre, M. J., Hasan, N. M., Kendrick, M. A., Stoker, S. W., & MacDonald, M. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.040394 · Cited by 27
Schaar, K., Geisler, A., Kraus, M., Pinkert, S., Pryshliak, M., Spencer, J. F., Tollefson, A. E., Ying, B., Kurreck, J., Wold, W. S. M., et al. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.07.002 · Cited by 25
“An improvement of transduction by increasing vector dose, use of AAV vectors with modified capsids,(55) or employment of small molecules(56) may increase levels of expressed anti-adenoviral amiRs in the liver and increase the antiviral effect, but it may also increase the risk of side effects.(52) In this regard, it s…”
Synthetic gene circuits as tools for drug discovery
Beitz, A. M., Oakes, C. G., & Galloway, K. E. (2021) · Trends in biotechnology · doi:10.1016/j.tibtech.2021.06.007 · Cited by 25
Exosomal and Non-Exosomal MicroRNAs: New Kids on the Block for Cancer Therapy
Syed, S. N., & Brüne, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094493 · Cited by 26
Development of AAV-Mediated Gene Therapy Approaches to Treat Skeletal Diseases
Lin, C., Greenblatt, M. B., Gao, G., & Shim, J. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.022 · Cited by 25
RNA interference as an anticancer therapy: a patent perspective
Dykxhoorn, D. M. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902838008 · Cited by 29
“The overexpression of shRNAs has, under some conditions, led to cytotoxic effects by overwhelming the RNAi machinery and impairing proper miRNA processing and function [174,175].”
BackgroundMachida, A., Kuwahara, H., Mayra, A., Kubodera, T., Hirai, T., Sunaga, F., Tajiri, M., Hirai, Y., Shimada, T., Mizusawa, H., et al. (2013) · Molecular Pain · doi:10.1186/1744-8069-9-36 · Cited by 27
“Although it is ultimately desirable to minimize target gene expression in adult mice, administration of high doses of AAV vectors interferes with endogenous microRNA processing, causing microRNA saturation and ultimately fatal liver toxicity because of the hepatotropism of AAV [25].”
BackgroundNóbrega, C., Codêsso, J. M., Mendonça, L. S., & de Almeida, L. P. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.157 · Cited by 28
“32 36–38 Considering these potential problems, this study investigated the safety profile of an shRNA targeting mutant ataxin-3, which had already been demonstrated to constitute an effective therapeutic strategy for MJD.”
Yan, H., Li, T., Wang, Y., Li, H., Xu, J., & Lu, X. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13159 · Cited by 25
Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors
Becker, J., Stanifer, M. L., Leist, S. R., Stolp, B., Maiakovska, O., West, A., Wiedtke, E., Börner, K., Ghanem, A., Ambiel, I., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.024 · Cited by 25
“The recipient scAAV vector genome contained two inverted BsmBI sites under a U6 promoter as well as a GFP reporter controlled by a Rous sarcoma virus (RSV) promoter and a minimal polyadenylation site.(59) Forward and reverse shRNA oligos (Table S1) were ordered from IntegratedDNATechnologies (Coralville, IA, USA) and…”
Self-citationNew Insights into Hbv Replication: New Opportunities for Improved Therapies
Nassal, M. (2008) · Future Virology · doi:10.2217/17460794.4.1.55 · Cited by 29
RNA interference based gene therapy for neurological disease
Jagannath, A., & Wood, M. J. A. (2007) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/elm005 · Cited by 26
“This suggested competition between expressed shRNAs and endogenous miRNAs, one explanation for which was found to be saturation of nuclear RNA exporter, exportin-5, by shRNAs, leading to down-regulation of miRNA expression [82].”
Background
Metadata
- Authors
- Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A.
- Affiliations
- Stanford Medicine (US)
- Universitätsklinikum Aachen (DE)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature
- Published
- 2006-05
- Volume
- 441
- Issue
- 7092
- Pages
- 537-541
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1971643509
- Cited by
- 1,677
- References
- 31
- Citations by year
- 2026: 27 · 2025: 32 · 2024: 49 · 2023: 35 · 2022: 57 · 2021: 36 · 2020: 45 · 2019: 54 · 2018: 54 · 2017: 60 · 2016: 75 · 2015: 94 · 2014: 92 · 2013: 121 · 2012: 121
- FWCI
- 57.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- RNA interference, shRNA, microRNA, XPO5, hepatotoxicity, liver injury, AAV8 vector, siRNA delivery, karyopherins, post-transcriptional gene silencing, mice, gene silencing therapy, dose-dependent toxicity
- MeSH terms
- Animals, Hepatitis B virus, Humans, Liver, Liver Regeneration, Mice, Transgenic, Nucleic Acid Conformation, RNA, Survival Analysis, Karyopherins, RNA Interference, MicroRNAs, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.